poster

Treatment Success and Psychiatric Stability in Adults with Tardive Dyskinesia: Post Hoc Analyses of Two Long-Term Valbenazine Studies

Abstract: Background: In clinical trials of valbenazine, which is approved for once-daily treatment of tardive dyskinesia (TD), psychiatric stability was assessed along with global change...

01/19/2023

Efficacy of Fremanezumab Quarterly and Monthly Dosing Regimens in Patients With Migraine and Psychiatric Comorbidities

Abstract: Introduction: Migraine with psychiatric comorbidities has been associated with increased disability, pain, and reduced quality-of-life.

01/19/2023

Fremanezumab for Preventive Migraine Treatment in Patients With Major Depressive Disorder: Baseline Patient Characteristics in the Phase 4 UNITE Study

Abstract: Introduction: Major depressive disorder (MDD) is a common migraine comorbidity. Fremanezumab, a humanized monoclonal antibody selectively targeting calcitonin gene-related pepti...

01/19/2023

Demographic and Practice Characteristics of Physician Assistants in the Psychiatric Workforce

Abstract: In recent years, demand for psychiatric care has been rapidly growing. At the same time, estimates show that 122 million people in the US reside in mental health professional sh...

01/19/2023

Continuity of Care Among Patients Newly Initiated on Second-Generation Oral or Long-Acting Injectable Antipsychotics During a Schizophrenia-Related Inpatient Stay

Abstract: BACKGROUND: Quality measures were compared between patients initiated on second-generation long-acting injectable antipsychotics (SGLAIs) and oral atypical antipsychotics (OAAs)...

01/19/2023

Lumateperone 42 mg in an Open-Label Switch Study in Patients With Stable Schizophrenia: Results by Previous Antipsychotic

Abstract: Background: Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and depressive episodes associated with bipolar I or bipolar II disorder. This analysis of open-...

01/19/2023

Metabolic Syndrome in Bipolar Depression With Lumateperone (ITI-007): A Post Hoc Analysis of 2 Randomized, Placebo-Controlled Trials

Abstract: Background: Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and depressive episodes associated with bipolar I or bipolar II disorder. This post hoc, pooled ...

01/19/2023

Assessing the Need for Repeat Treatment Courses with Zuranolone in Adult Patients With Major Depressive Disorder With Elevated Anxiety: An Analysis of the Open-Label, Phase 3 SHORELINE Study

Abstract: Introduction Zuranolone is an investigational neuroactive steroid and positive allosteric modulator of synaptic and extrasynaptic GABAA receptors in clinical development as an o...

01/19/2023

Effect of daridorexant on sleep and daytime functioning in older adults with insomnia disorder

Abstract: As insomnia affects elderly more than younger adults, therapeutic options with limited safety risks are needed to treat this patient group. We report elderly subgroup analyses f...

01/19/2023

Trazodone prescribing in insomnia: a real-world cohort study

Abstract: Trazodone is indicated for depressive disorder (150-400 mg/day) but is often prescribed off-label to treat insomnia at “low dose” (

01/19/2023

Tracks

Major Depressive Disorder

General Psychiatry

ADHD

MDD Insights

Schizophrenia Insights

About

Celebrating 35 years of empowering the highest standard in mental healthcare, Psych Congress serves as a unique, integrated forum to connect members of the entire mental health team—bringing together psychiatrists, nurse practitioners, physician assistants, psychologists, primary care physicians, and other mental health professionals for 4 days of practical education to improve patient care.

December 9 ⁠–⁠ December 11

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

May 28 ⁠–⁠ May 31

See Full Calendar

poster

Tracks

About

Specialties

Events

Year Round Education

HMP Global Products